NCT03310957 2025-12-12Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerSeagen Inc.Phase 1/2 Completed185 enrolled 23 charts
NCT04032704 2025-03-10A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsSeagen Inc.Phase 2 Terminated205 enrolled 54 charts